Of 41 children with short bowel syndrome treated with the peptide teduglutide at one center, 21 weaned off intravenous feeding entirely. Short bowel syndrome means a child has lost so much small intestine, often to a birth defect or surgery in infancy, that food alone cannot supply enough nutrients. The fix is parenteral nutrition: calories pumped straight into a vein, frequently for years, through a permanent line that carries its own risks of bloodstream infection, sepsis, and liver damage. Getting a child off that line is the whole goal of treatment, and half of this group got there.
The drug is teduglutide ↗, sold as Gattex in the United States and Revestive in Europe. It is an engineered version of GLP-2, a hormone the gut releases after meals that tells the intestinal lining to grow taller and absorb more. Natural GLP-2 breaks down in minutes. Teduglutide is rebuilt to last hours, so a daily injection keeps the growth signal switched on. It acts on the GLP-2 receptor ↗, a cousin of the GLP-1 receptor that the obesity and diabetes drugs target, but with a different job entirely: rebuilding bowel, not curbing appetite.
The numbers come from a retrospective cohort published June 11 in Intestinal Failure ↗, covering 41 of 161 short-bowel children managed at a single tertiary center between 2018 and 2022. Over a median follow-up of about two and a half years, 21 children (51.2 percent) came off parenteral nutrition completely, and 24 (65 percent) cut their intravenous calories by at least a fifth. The median time to full weaning was 7.3 months. No treatment-related adverse events were reported, though 12 percent of children needed more intravenous support again over the follow-up.
The more useful finding is who responded. Two baseline factors predicted how fast a child weaned: how much of their daily calories came from the IV line when treatment started, and how much small bowel they had left. A child leaning less on parenteral nutrition and carrying more residual intestine got off the line sooner. That is the kind of detail a registration trial, with its fixed enrollment and short window, tends to flatten, and it is what a clinician deciding whether to start an expensive daily injection actually wants to know.
The caveats are real. This is one center, 41 children, looking backward at records rather than running a controlled experiment. The Food and Drug Administration cleared teduglutide for children one year and older in 2019, on the strength of a 24-week trial in 59 patients run by Takeda, the drug's maker. The value of a cohort like this is the longer view, roughly two and a half years of real-world follow-up, where you can see who stays off the line and who drifts back. A single-center series cannot tell you whether these weaning rates hold everywhere, only that in unselected practice, outside a trial protocol, about half of treated children reached independence.
That is the quiet contrast worth drawing. GLP-1 drugs dominate the peptide conversation because tens of millions of adults take them for weight. Teduglutide treats a few thousand patients, many of them infants and small children, for a condition most people have never heard of. Same hormone family, a neighboring receptor, and a result that for one child means pulling a central line for good rather than living tethered to a pump.